IPO Zafgen, Inc. (ZFGN) is a biopharmaceutical company dedicated to improving the health and well-being of patients affected by obesity. Beloranib, their lead product candidate, is a novel, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia, or insatiable life-threatening hunger and hunger-related behaviors, in Prader-Willi Syndrome, or PWS, craniopharyngioma-associated obesity, and severe obesity in the general population.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
No comments:
Post a Comment